Conflict-of-interest policies protect docs from big pharma influence

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.671, 2013-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Optimizing DMPK Properties: Experiences from a Big Pharma DMPK Department

Current Drug Metabolism, Vol. 17, Iss. 3, 2016-03 ,pp. : 253-270

Bentham Science Publishers

Access to resources Recommend Favorite

Big Pharma's Recent Challenges

Applied Clinical Research, Clinical Trials and Regulatory Affairs, Vol. 1, Iss. 1, 2014-04 ,pp. : 28-36

Bentham Science Publishers

Access to resources Recommend Favorite

Meta-Analyses and Conflict of Interest

By Fava Giovanni A.

CNS Drugs, Vol. 26, Iss. 2, 2012-02 ,pp. : 93-96

Adis International

Access to resources Recommend Favorite

Conflict of Interest and Oncology Guidelines

By Burstein Harold J.

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 10, 2008-11 ,pp. : 955-955

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Drug price cuts in Japan affect big pharma

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 356, 2002-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite